PharmPro, September 2011
After working for 2 years as the Global Director of Strategy and Marketing for a Contract Manufacturing Organization, I saw a gap in the way CROs/CMOs engage with Big Pharma and Biotech companies in outsourcing projects.
The team at Nice Insight had the idea to develop a tool that would assist drug developers (emerging to large scale) to efficiently target outsourcing partners across the globe. After a year of development, with a small but dedicated staff, we launched Nice Insight in March 2011. We are now in our third quarter of business and on September 15th we will release our latest quarterly update to our report.
This interactive reporting tool is not meant to replace or circumvent the current selection criteria or processes used by drug developers such as BMS to select outsourcing candidates. Rather, it will enhance your efforts by reducing inherent costs, in terms of time and money spent, in locating potential development partners.
These reports also give drug developers access to a first-level evaluation of contract
research and manufacturing organizations by their peers, which significantly reduces
screening efforts. (Data is collected quarterly from a pool of 40,000 pharmaceutical and biotechnology executives across 350+ companies.)
The proprietary intelligence gives CMOs CROs insight into what their audience thinks
about them and their perceived performance relative to their competitors. For Big Pharma companies, biotechs and others that outsource, quarterly report data of this breadth fundamentally helps with screening and selection of partners. All groups interested in the pharma and biotech market can also benefit from key trending information on what's being spent where, along with market share-enabling industry benchmarking.
I believe this rare, unbiased data will help all parties make a more informed and strategic decision when choosing outsourcing partners. We look forward to providing updated blog posts that highlight trends in our data.
